Table 1:

Baseline characteristics between the 2 groups^{^a}

	Total (n = 114)	UK Group (MT+UK+MT) (n = 45)	Non-UK Group (MT+MT) (n = 69)	P Value
Age^{^b}	75 (65–81)	74 (63–81)	75 (65–82)	.615
Male	56 (49.1)	21 (46.7)	35 (50.7)	.672
Risk factor
Hypertension	59 (51.8)	23 (51.1)	36 (52.2)	.912
Diabetes	27 (23.7)	12 (26.7)	15 (21.7)	.545
Dyslipidemia	20 (17.5)	10 (22.2)	10 (14.5)	.289
Smoking	15 (13.2)	7 (15.6)	8 (11.6)	.541
Coronary artery disease	9 (7.9)	3 (6.7)	6 (8.7)	1.000
Atrial fibrillation	72 (63.2)	26 (57.8)	46 (66.7)	.336
TOAST
LAA	0 (0.0)	0 (0.0)	0 (0.0)
CA	77 (67.5)	29 (64.4)	48 (69.6)	.568
SUD	19 (16.7)	6 (13.3)	13 (18.8)	.441
Cancer-related stroke	17 (14.9)	9 (20.0)	8 (11.6)	.218
IV tPA	29 (25.4)	9 (20.0)	20 (29.0)	.282
Admission NIHSS^{^b}	15 (12–18)	15 (10–18)	15 (12–19)	.080
Baseline ASPECTS^{^b}	8 (7–9)	8 (7–9)	8 (7–9)	.328
Occlusion site				.182
ICA	42 (36.8)	12 (26.7)	30 (43.5)
M1	45 (39.5)	20 (44.4)	25 (36.2)
M2	27 (23.7)	13 (28.9)	14 (20.3)

Note:—TOAST indicates Trial of Org 10172 in Acute Stroke Treatment³¹; LAA, large-artery atherosclerosis; CA, cardioembolism; SUD, stroke of undetermined etiology.
↵a Values in parentheses represent the number of patients (%).
↵b Data are median and numbers in parentheses are IQR.